186 related articles for article (PubMed ID: 20606660)
1. Editorial: just how "difficult" is it to withdraw PPI treatment?
Howden CW; Kahrilas PJ
Am J Gastroenterol; 2010 Jul; 105(7):1538-40. PubMed ID: 20606660
[TBL] [Abstract][Full Text] [Related]
2. It is difficult to discontinue PPI treatment in patients with GERD.
Bjornsson E
Am J Gastroenterol; 2011 Feb; 106(2):367-8; author reply 368. PubMed ID: 21301460
[No Abstract] [Full Text] [Related]
3. Clinical and pathophysiological consequences of on-demand treatment with PPI in endoscopy-negative reflux disease. Is rebound hypersecretion of acid a problem?
Juul-Hansen P; Rydning A
Scand J Gastroenterol; 2011 Apr; 46(4):398-405. PubMed ID: 21142586
[TBL] [Abstract][Full Text] [Related]
4. Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.
Emerson CR; Marzella N
Clin Ther; 2010 Aug; 32(9):1578-96. PubMed ID: 20974316
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review.
van der Pol RJ; Smits MJ; van Wijk MP; Omari TI; Tabbers MM; Benninga MA
Pediatrics; 2011 May; 127(5):925-35. PubMed ID: 21464183
[TBL] [Abstract][Full Text] [Related]
6. Gradual cessation of proton pump inhibitor (PPI) treatment may prevent rebound acid secretion, measured by the alkaline tide method, in dyspepsia and reflux patients.
Niv Y
Med Hypotheses; 2011 Sep; 77(3):451-2. PubMed ID: 21723045
[TBL] [Abstract][Full Text] [Related]
7. Impact of dialysis on gastroesophageal reflux, dyspepsia, and proton pump inhibitor treatment in patients with chronic renal failure.
Strid H; Fjell A; Simrén M; Björnsson ES
Eur J Gastroenterol Hepatol; 2009 Feb; 21(2):137-42. PubMed ID: 19212202
[TBL] [Abstract][Full Text] [Related]
8. Pantoprazole: a proton pump inhibitor with oral and intravenous formulations.
Devault KR
Expert Rev Gastroenterol Hepatol; 2007 Dec; 1(2):197-205. PubMed ID: 19072410
[TBL] [Abstract][Full Text] [Related]
9. Omeprazole-Mg 20.6 mg is superior to lansoprazole 15 mg for control of gastric acid: a comparison of over-the-counter doses of proton pump inhibitors.
Miner PB; McKean LA; Gibb RD; Erasala GN; Ramsey DL; McRorie JW
Aliment Pharmacol Ther; 2010 Apr; 31(8):846-51. PubMed ID: 20146702
[TBL] [Abstract][Full Text] [Related]
10. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
Bytzer P; van Zanten SV; Mattsson H; Wernersson B
Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
[TBL] [Abstract][Full Text] [Related]
11. Concomitant Administration of a Histamine2 Receptor Antagonist and Proton Pump Inhibitor Enhances Gastric Acid Suppression.
Abdul-Hussein M; Freeman J; Castell D
Pharmacotherapy; 2015 Dec; 35(12):1124-9. PubMed ID: 26621819
[TBL] [Abstract][Full Text] [Related]
12. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial.
Niklasson A; Lindström L; Simrén M; Lindberg G; Björnsson E
Am J Gastroenterol; 2010 Jul; 105(7):1531-7. PubMed ID: 20332770
[TBL] [Abstract][Full Text] [Related]
13. Maintenance treatment with proton pump inhibitors for reflux esophagitis in pediatric patients: a systematic literature analysis.
Illueca M; Wernersson B; Henderson C; Lundborg P
J Pediatr Gastroenterol Nutr; 2010 Dec; 51(6):733-40. PubMed ID: 20808247
[TBL] [Abstract][Full Text] [Related]
14. pH, healing rate, and symptom relief in patients with GERD.
Huang JQ; Hunt RH
Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580
[TBL] [Abstract][Full Text] [Related]
15. AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.
Targownik LE; Fisher DA; Saini SD
Gastroenterology; 2022 Apr; 162(4):1334-1342. PubMed ID: 35183361
[TBL] [Abstract][Full Text] [Related]
16. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.
Freedberg DE; Kim LS; Yang YX
Gastroenterology; 2017 Mar; 152(4):706-715. PubMed ID: 28257716
[TBL] [Abstract][Full Text] [Related]
17. Voluntary and controlled weight loss can reduce symptoms and proton pump inhibitor use and dosage in patients with gastroesophageal reflux disease: a comparative study.
de Bortoli N; Guidi G; Martinucci I; Savarino E; Imam H; Bertani L; Russo S; Franchi R; Macchia L; Furnari M; Ceccarelli L; Savarino V; Marchi S
Dis Esophagus; 2016; 29(2):197-204. PubMed ID: 25516110
[TBL] [Abstract][Full Text] [Related]
18. Dexlansoprazole for the treatment of esophagitis and GERD.
Davies SL
Drugs Today (Barc); 2010 Feb; 46(2):75-80. PubMed ID: 20393635
[TBL] [Abstract][Full Text] [Related]
19. [Adverse events associated with long-term use of proton pump inhibitors].
Reimer C; Bytzer P
Ugeskr Laeger; 2012 Sep; 174(39):2289-93. PubMed ID: 23006222
[TBL] [Abstract][Full Text] [Related]
20. Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors.
Thjodleifsson B
Drugs Aging; 2002; 19(12):911-27. PubMed ID: 12495367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
